title: Oxygen reduction and lipid peroxidation by iron chelates with special reference to ferric nitrilotriacetate.
abstract: A certain iron chelate, ferric nitrilotriacetate (Fe3+-NTA) is nephrotoxic and also carcinogenic to the kidney in mice and rats, a distinguishing feature not shared by other iron chelates tested so far. Iron-promoted lipid peroxidation is thought to be responsible for the initial events. We examined its ability to initiate lipid peroxidation in vitro in comparison with that of other ferric chelates. Chelation of Fe2+ by nitrilotriacetate (NTA) enhanced the autoxidation of Fe2+. In the presence of Fe2+-NTA, lipid peroxidation occurred as measured by the formation of conjugated diene in detergent-dispersed linoleate micelles, and by the formation of thiobarbituric acid-reactive substances in the liposomes of rat liver microsomal lipids. Addition of ascorbic acid to Fe3+-NTA solution promoted dose-dependent consumption of dissolved oxygen, which indicates temporary reduction of iron. On reduction, Fe3+-NTA initiated lipid peroxidation both in the linoleate micelles and in the liposomes. Fe3+-NTA also initiated NADPH-dependent lipid peroxidation in rat liver microsomes. Although other chelators used (deferoxamine, EDTA, diethylenetriaminepentaacetic acid, ADP) enhanced autoxidation, reduction by ascorbic acid, or in vitro lipid peroxidation of linoleate micelles or liposomal lipids, NTA was the sole chelator that enhanced all the reactions.
authors.affiliation: Department of Pathology, Faculty of Medicine, Kyoto University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Hamazaki
authors.forename: S
authors.initials: S
authors.lastname: Okada
authors.forename: J L
authors.initials: JL
authors.lastname: Li
authors.forename: S
authors.initials: S
authors.lastname: Toyokuni
authors.forename: O
authors.initials: O
authors.lastname: Midorikawa
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology; D003676:Deferoxamine / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D005290:Ferric Compounds / Q000494:pharmacology* / Q000633:toxicity; D007502:Iron Chelating Agents / Q000494:pharmacology*; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D008081:Liposomes / Q000378:metabolism; D008563:Membrane Lipids / Q000378:metabolism; D008823:Micelles; D008862:Microsomes, Liver / Q000032:analysis; D009249:NADP / Q000494:pharmacology; D009571:Nitrilotriacetic Acid / Q000031:analogs & derivatives*; D010084:Oxidation-Reduction; D010100:Oxygen / Q000378:metabolism*; D004369:Pentetic Acid / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D005290:Ferric Compounds; D007502:Iron Chelating Agents; D008041:Linoleic Acids; D008081:Liposomes; D008563:Membrane Lipids; D008823:Micelles; D009249:NADP; D000244:Adenosine Diphosphate; D004369:Pentetic Acid; D004492:Edetic Acid; D019787:Linoleic Acid; D003676:Deferoxamine; D009571:Nitrilotriacetic Acid; D001205:Ascorbic Acid; D010100:Oxygen; C020326:ferric nitrilotriacetate